explore
 
  • Tasigna Daily Planner

    The Tasigna Daily Planner is a web-app that works from any device, from your smartphone to your laptop or tablet. Use it to plan your Tasigna dosing schedule.

    Start Now (no download necessary)
 
  • Patients with BCR-ABL ≤ 10% at 3 months with Tasigna vs Imatinib

    Early Molecular Response (EMR) in CML

    ENESTnd participants without evaluable PCR samples at 3 months were excluded from the Landmark Analysis.3 TASIGNA 400 mg BID ENESTnd study arm is not reported here as this dose is not indicated for newly diagnosed patients.1

  • ENESTnd Landmark Analysis Patients Alive by 5 years1

    Early Molecular Response (EMR) in CML

    *Pooled analysis of patients on TASIGNA 300 mg BID and imatinib.

References
  1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; August 2014;
  2. Baccarani M, et al. Blood. 2013; 122(6):872-884;
  3. Hughes T, et al. Blood. 2014: 123(9):1353-1359.
 
  • Cumulative Rate of MMR by 5 Years in ENESTnd1

    ENESTnd MMR Rates 5 Years
  • Percent of Patients With MMR by 1 Year in ENESTnd1

    Major Molecular Response 1 Year Tasigna
  • Cumulative Rate of MR4.5 by 5 Years in ENESTnd1

    CML MR 4.5 Randomization
  • Percent of Patients With MR4.5 by 5 Years in ENESTnd1

    MR 4.5 Nilotinib vs Imatinib
References
  1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; August 2014.
 
  • 99% of patients treated with TASIGNA 300 mg BID1

    Remained In Chronic Phase at 5 Years (n = 282)1

    Chronic Phase CML and Tasigna Chronic Phase CML and Tasigna Chronic Phase CML and Tasigna

    *In patients still receiving study treatment.

  • Patients Who Progressed1

    CML Progression on Tasigna
References
  1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; August 2014.
  2. Larson RA, et al. JCO. 2013;31(18s) [abstract 7052].
  3. Larson RA, et al. JCO. 2014;32(5s) [abstract 7073].
 

Progression from Chronic to Blast Crisis in Chronic Myeloid Leukaemia

Learn how CML progresses from chronic phase to accelerated to blast crisis. Also learn how BCR-ABL inhibition can help prevent patients from progressing.

 
VIDEO TRANSCRIPT

The key cause and driver of chronic myeloid leukemia (CML), a potentially deadly disease, is a specific chromosomal abnormality that encodes the BCR-ABL fusion protein. After treatment, even if a small number of BCR-ABL–positive cells remain, patients with CML can progress from a manageable chronic phase through a more aggressive accelerated phase, and into a fatal blast crisis. “CML after progression is considered the most resistant form of acute leukemia. So, a sudden transition between a normal life—work, family, friends, sports, everything—to a condition of no way out.” Patients who progress have symptoms typical of an acute leukemia such as unexplained fever, night sweats, and infections, bleeding, bone pain, weight loss, splenomegaly, shortness of breath, and fatigue, which can very quickly lead to death. “To communicate the disaster, you need a lot of energy. You were losing as a physician, a patient, and sometimes or frequently, a friend. So, really a sad situation, you can imagine.”

As shown in ENESTnd—a randomized, multicenter registrational trial of Tasigna versus imatinib in newly diagnosed CML patients in chronic phase—survival is at risk once a patient progresses, so keeping patients in the chronic phase is vital. “So, to prevent progression, this is the first and the most important endpoint.” Compared with imatinib, the selective and potent BCR-ABL inhibitor Tasigna, binds more tightly to powerfully inhibit this abnormal protein and the overproduction of leukemic cells. As shown in ENESTnd, compared with imatinib, patients treated with Tasigna have a significantly reduced risk of progression to advanced disease, allowing them to remain in the chronic phase. For information on the safety of Tasigna and if it is the right choice for you or your patient to reduce the risk of progression, please visit Tasigna.com.